Masimo Secures FDA 510(k) Clearance for smartSedLine to Support Brain Health During Anesthesia; FDA Grants 510(k) Clearance to Fziomed’s Dynavisc® Tendon Protector; FAMID Biomedical Technology Achieves Class C IVD IVDR Certification with DNV’s Support; Haemonetics Announces CE Mark Approval for VASCADE MVP® XL Closure System; i-Lumen Presents i-SIGHT Feasibility Study Findings at CTS Retina 2026; Argá Medtech Completes Enrollment in Paroxysmal AF Cohort of COHERENT-AF Pivotal IDE Study

  • Home Blog Medtech news for masimo fziomed dnv

Masimo Secures FDA 510(k) Clearance for smartSedLine to Support Brain Health During Anesthesia; FDA Grants 510(k) Clearance to Fziomed’s Dynavisc® Tendon Protector; FAMID Biomedical Technology Achieves Class C IVD IVDR Certification with DNV’s Support; Haemonetics Announces CE Mark Approval for VASCADE MVP® XL Closure System; i-Lumen Presents i-SIGHT Feasibility Study Findings at CTS Retina 2026; Argá Medtech Completes Enrollment in Paroxysmal AF Cohort of COHERENT-AF Pivotal IDE Study

Nov 19, 2026

Masimo Received FDA 510(k) Clearance for smartSedLine™ to Advance Brain Health During Anesthesia 

On 18 November 2026, Masimo received FDA 510(k) clearance for its next-generation smartSedLine brain function monitoring solution, designed to improve the assessment of patients’ responses to anesthesia during surgical procedures. The technology incorporated an enhanced Patient State Index (PSi) algorithm that enabled faster detection of changes in brain activity during anesthesia induction and delivered more stable measurements under low electroencephalography (EEG) signal conditions. The solution helped clinicians evaluate sedation depth more effectively and make informed decisions regarding individualized anesthesia management, particularly for elderly and high-risk patients. It was introduced through a dedicated monitoring module and EEG sensor compatible with Masimo’s Root monitoring platform, which also supported integration with its O3 Regional Oximetry technology.

“Every patient responds differently to anesthesia, and understanding those individual responses is critical to optimizing depth of sedation and informing care,” said Dr. Basil Matta, Chief Medical Officer, Masimo, a Danaher company. “By providing clinicians with more responsive and stable information about brain activity, smartSedLine’s faster PSi response allows clinicians to optimize anesthesia from induction throughout the intraoperative period. This earlier insight into a patient’s sedation state makes it easier to provide individualized patient care, which may improve hemodynamic stability in high-risk patients and those with vulnerable brains. This is truly a novel approach to care.”

As per DelveInsight’s “Brain Monitoring Devices Market Report,” the global brain monitoring devices market was valued at USD 6.78 billion in 2025 and is projected to reach USD 12.75 billion by 2034. The market is expected to expand at a CAGR of 7.27% during the forecast period 2026-2034, supported by rising prevalence of neurological disorders such as multiple sclerosis, epilepsy, and dementia, rising incidence of traumatic brain injury and stroke, growing awareness of these disorders, and continuous product development.

Fziomed Announced FDA 510(k) Clearance for Dynavisc® Tendon Protector in the United States 

On 18 November 2026, Fziomed received FDA 510(k) clearance for its Dynavisc Tendon Protector, expanding its surgical biomaterials portfolio in the United States. The product was a fully synthetic, ready-to-use, absorbable gel developed using the company’s proprietary dual-polymer technology. It was designed to protect tendons, ligaments, and skeletal muscles following surgical procedures by forming a temporary barrier between adjacent tissues. The technology was intended to minimize postoperative scar tissue formation, support tendon healing, preserve tissue movement, and improve functional recovery. The product had already been used in more than 50,000 patients internationally, supported by clinical publications evaluating tendon healing and functional outcomes.

“FDA clearance of Dynavisc represents another important milestone for Fziomed as we continue expanding our portfolio of innovative biomaterial technologies in the United States,” said Ryan Bledsoe, Vice President of Marketing and Market Access at Fziomed. “Dynavisc has a long history of clinical use internationally, and we are excited to bring this established technology to the U.S. market. Its fully synthetic composition, ready-to-use formulation, and ease of application offer surgeons a compelling and differentiated alternative solution for tissue separation and protection following tendon repair procedures.”

As per DelveInsight’s “Surgical Sealant and Adhesives Market Report,” the global surgical sealant and adhesives market was valued at USD 2.18 billion in 2023, growing at a CAGR of 7.58% during the forecast period from 2024 to 2030 to reach USD 3.39 billion by 2030. The surgical sealant and adhesives market is slated to witness prosperity owing to the growing prevalence of chronic health problems such as cardiovascular problems, kidney problems, neurological issues, and others. The rise in road accidents requiring urgent surgeries is another factor in the growth of the surgical sealant and adhesives market. The continuous rise in cosmetic surgeries and growing focus on improving the safety, affordability, and usability of surgical sealants and adhesives are further expected to result in appreciable revenue growth in the Surgical Sealant and Adhesives Market during the forecast period (2024-2030).

DNV Supported FAMID Biomedical Technology in Achieving IVDR certification for its Class C IVD in six Months 

On 18 November 2026, DNV supported FAMID Biomedical Technology (Tianjin) Co., Ltd. in obtaining IVDR certification for its E7 Oncoprotein Rapid Test Kit within six months. The Class C IVD product was developed to support the early detection of cervical cancer by identifying HPV E7 oncoprotein in cervical cell samples. The certification followed an assessment of the company’s quality management system, clinical evidence, and technical documentation. The approval enabled the company to strengthen its access to European markets, with the test intended for both professional laboratory applications and self-testing.

“Bringing medical technologies to market requires not only strong technical capabilities, but also a certification partner who understands the importance of timely market access. Working with DNV has been a highly positive experience. Their professionalism, technical expertise, and collaborative approach gave us confidence throughout the certification process and helped us progress efficiently towards bringing our technology to market. For our business, having a reliable and responsive partner is invaluable as we continue to develop our business and expand into new markets.

As per DelveInsight’s “In Vitro Diagnostics Market Report,” the global in vitro diagnostics market was valued at USD 71.01 billion in 2024, growing at a CAGR of 4.71% during the forecast period from 2025 to 2032, to reach USD 93.60 billion by 2032. The in vitro diagnostics market is estimated to register positive revenue growth owing to factors such as rising prevalence of various infectious diseases such as COVID-19, growing prevalence of various cancers, increasing cases of hematological diseases, and increasing product development activities with respect to in vitro diagnostics, among others.

Haemonetics Announced CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System  

On 18 November 2026, Haemonetics Corporation received CE Mark certification under the European Medical Device Regulation (EU-MDR) for its VASCADE MVP XL Venous Vascular Closure System, enabling its commercialization across the European Union and other CE-recognizing regions. The company also completed the first commercial procedures using the device in Germany, Italy, and the United Kingdom in October 2026. The system was developed to close femoral venous access sites following catheter-based procedures involving larger vascular sheaths of 10–12F inner diameter. It incorporated 58% more collagen and a 9% larger closure disc than the existing VASCADE MVP system, providing enhanced closure capabilities for complex procedures, including cryoablation, pulsed field ablation (PFA), and left atrial appendage closure (LAAC). The technology was designed to achieve faster hemostasis, reduce post-procedure recovery time, facilitate earlier patient mobility, and support same-day hospital discharge.

“VASCADE MVP XL has driven the growth of our Interventional Technologies business in the United States, delivering physicians key benefits in larger-bore venous closure supported by clinical evidence. With CE Mark certification and the first cases completed in Europe, we look forward to significantly expanding our impact and commercial momentum in electrophysiology and interventional cardiology as we help raise standards of care for a larger population of patients in new markets around the world,” said Ken Crowley, Vice President and General Manager, Interventional Technologies at Haemonetics.

According to DelveInsight’s “Interventional Cardiology Devices Market Report”, the global interventional cardiology devices Market was valued at USD 21.62 billion in 2025 and is projected to reach USD 40.06 billion by 2034. The Interventional Cardiology Devices Market is expected to expand at a CAGR of 7.09% during the forecast period 2026-2034, supported by the growing prevalence of cardiovascular disease and its risk factors, the increasing preference for minimally invasive procedures, technological advancement in product design, and strategic activity among key manufacturers.

i-Lumen i-SIGHT Feasibility Study Results Presented at CTS Retina 2026 

On 10 November 2026, i-Lumen Scientific presented the feasibility study results of its i-SIGHT clinical investigation at the 2026 Clinical Trials at the Summit Retina meeting. The multicenter, randomized, sham-controlled study evaluated the safety and potential effectiveness of the company’s investigational i-Lumen AMD System in 30 patients with intermediate to advanced dry age-related macular degeneration across 10 clinical centers in the United States. The device delivered non-invasive, low-level microcurrent stimulation through the eyelid to influence retinal electrical signaling and support photoreceptor function.

The study demonstrated a mean improvement of 9.62 ETDRS letters in visual acuity in the actively treated eyes at Month 3. More than 50% of treated participants achieved an improvement of at least 10 letters in best-corrected visual acuity at one or more follow-up visits between Months 2 and 12. Exploratory imaging analyses also showed improvements in retinal structural biomarkers, while retinal electrophysiology findings indicated positive changes in photoreceptor response. No unexpected device-related adverse events were reported, and adverse event rates remained comparable between the active treatment and sham groups.

Following these findings, i-Lumen Scientific advanced its clinical development program by initiating the larger pivotal i-SIGHT2 study, which was enrolling participants in the United States and the United Kingdom.

“These findings from a feasibility study suggest that retinal bioelectric stimulation may influence visual function in patients with intermediate to advanced dry AMD,” said Dr. Bakri. “While the study was not designed to establish definitive efficacy, the signals observed in visual acuity, retinal electrophysiology, and imaging biomarkers support further evaluation in larger controlled clinical trials.”

According to DelveInsight’s “Ophthalmic Devices Market Report”, the ophthalmic devices market is estimated at USD 34.50 billion in 2025 and is projected to reach USD 54.80 billion by 2034. Growth is anchored in the rising global prevalence of cataract, glaucoma, and retinal disorders, the accelerating myopia epidemic, an aging population, and continuous technological advancement in surgical, diagnostic, and lens-based eye-care solutions. Ophthalmic devices encompass the specialized medical instruments and implants used to diagnose, monitor, and treat disorders of the eye and visual system. Because ocular conditions such as cataract, glaucoma, retinopathies, age-related macular degeneration, and refractive error affect a growing share of the aging and screen-exposed global population, hospitals, specialty eye clinics, and ambulatory surgical centers rely on an expanding toolkit of surgical devices, diagnostic and monitoring systems, and corrective lenses to deliver precise, minimally invasive eye care. 

Argá Medtech Completed Enrollment of Paroxysmal AF Cohort in the COHERENT-AF Pivotal IDE Study 

On 11 November 2026, Argá Medtech completed enrollment of 150 participants across 27 clinical sites in the United States and Europe for the paroxysmal atrial fibrillation cohort of its pivotal COHERENT-AF IDE study. The clinical investigation evaluated the safety and effectiveness of the company’s Coherent Sine Burst Electroporation Platform, which utilized sine wave-based pulsed field ablation technology for treating drug-refractory atrial fibrillation. The study also included a persistent atrial fibrillation cohort, whose enrollment was ongoing at the time. The completion of the first cohort marked an important clinical development milestone and supported the company’s progress toward future FDA and CE Mark regulatory submissions.

“Completing enrollment in the paroxysmal AF cohort is an important milestone for COHERENT-AF,” said Emile Daoud, MD, Director of Electrophysiology Research, Hatton Research Institute at Bethesda North Hospital, Cincinnati, Ohio, and the leading enroller in COHERENT-AF. “In our procedures, the CSE Platform has consistently delivered pulmonary vein isolation with a streamlined, single-catheter workflow, and the ability to address the pulmonary veins, posterior wall, and cavo-tricuspid isthmus without exchanging catheters has been a meaningful advantage in our lab. We look forward to the completion of the persistent AF cohort and the 12-month effectiveness results.”

According to DelveInsight’s “Ablation Devices Market Report,” the global ablation devices market size is expected to increase from USD 8,090.31 million in 2025 to USD 15,347.69 million by 2034, reflecting strong and sustained growth. The global ablation devices market is growing at a CAGR of 8.38% during the forecast period from 2026 to 2034. The market for ablation device solutions is being primarily driven by the rising prevalence of chronic diseases such as cancer and cardiovascular diseases, and increasing technological advancements globally.

loader